Popular Articles
Teeth Whitening Products

UGA Grad Program Expands To Prepare Teachers To Work With Secondary Students With Autism
An innovative University of Georgia graduate program in special education that has prepared scores of Georgia teachers to work with elementary-age students with autism over the last several years has received a new 4-year, $793,000 federal grant to train teachers to work with similarly challenged secondary-age students.
generic viagra online
Protons In The War On Cancer
Latest research on proton therapy highlights medical physics meeting next week in Anaheim
News of the day
Celleron Therapeutics And Astrazeneca Announce Personalised Medicine Collaboration In Cancer For The Development Of AZ's Leading HDAC Inhibitor
Celleron Therapeutics Ltd, the Oxford UK based specialist in the development of individually targeted cancer medicines, has secured exclusive rights to AstraZeneca plc"s lead histone deacetylase (HDAC) inhibitor (AZD 9468), for global development in conjunction with its proprietary "CancerNav" predictive biomarker platform. "CancerNav" specifically identifies those tumours which are most likely to respond to an individual cancer drug, thereby enabling a highly focussed clinical development and commercialisation programme, based on a closely linked diagnostic and therapeutic "personalised medicine" approach.
Endocrinology

New England Cord Blood Bank Installs Automated Cord Blood Processing Line

New England Cord Blood Bank, Inc. (NECBB), a global cord blood processing and storage facility, announced today that it will be implementing an automated blood processing system at the company"s Newton facility. The AutoXpress™ System (AXP), developed by ThermoGenesis Corp. and distributed by GE Healthcare, is a state-of-the-art, fully closed and sterile system that will provide automated cell separation and processing for cord blood samples, ensuring quality and consistency in cord blood processing while maximizing the yield of valuable stem cells from the cord blood. "Families entrust us with a precious gift for safekeeping," said John Rizza, President of the New England Cryogenics Center, Inc., the parent company of NECBB. "We are pleased to be able to offer our clients the added level of confidence and security that this advanced technology provides." AXP is fast, precise, and - according to data provided by New York Blood Center - can harvest greater than 97% of the mononucleated cell (MNC) population, which is rich in stem cells, without the use of additives. By automating the process, AXP minimizes the risk of contamination and ensures predictable and reliable results. Further, the system captures essential data for quality assurance and compliance with current good tissue practices. NECBB will begin processing samples with AXP in August. In addition to the automation, NECBB will continue to operate their manual system, which will allow for processing of samples too small for the automated system. NECBB currently accepts and processes private cord blood samples from parents looking to preserve stem cells from their newborn"s cord blood, which are then available for the family to use at any time. Implementation of the automated system also brings NECBB one step closer to accreditation as a public cord blood bank. "We are excited at the possibilities afforded us by installing the AXP system," added Rizza. "It is our goal to ensure that we provide families with all possible options, and with the information they need to make the choice that fits best for them." Cord blood banking, both simple and secure, is a life-giving opportunity that happens at the time of birth. It offers a powerful medical re in fighting both chronic and acute diseases that may develop within the child or a family member. Currently, cord blood is used to treat over 80 diseases including sickle cell anemia, leukemia and various cancers. New England Cord Blood Bank


Add your comment:
Name:
Site address: http://
Your message:
Enter today\\\\'s date, 2 digits
(spam protection):